Avandia Cases | Claims Are Settling

Latest News as of September 24, 2010

On September 24th 2010, the FDA stated it will significantly restrict Avandia use for only patients who cannot control their type 2 diabetes with any other medications. This is because of all the data and reports and studies indicating the risk of heart attack, stroke and congestive heart failure.

Latest News as of July 21, 2010

The manufacturer of Avandia, Glaxo Smith Kline, has settled over 5,000 Avandia cases to date. They have taken a reported legal charge of at least 2.2 billion as stated in their public reporting due to Avandia settlement.

Glaxo Smith Kline is the United Kingdom’s largest pharmaceutical corporation.

GSK’s chief counsel said that their settlement approach is in the best interest of the company.

Our law firm has settled many Avandia cases with Glaxo Smith Kline. If you or your loved one has taken Avandia, you need to contact us today at 800-718-4658 to speak to an Avandia intake specialist.

Latest News as of July 13, 2010

A former FDA official said at an FDA hearing that Galaxo, manufacturer of Avandia withheld from FDA regulators information which implied that Avandia posed an increased risk for serious heart problems. Currently, FDA experts are debating whether or not Avandia should be pulled from the market because of these side effects including congestive heart failure, strokes, and heart attacks.

Evidence is slowly revealing that Galaxo did not provide the FDA with all the information that it knew at the time of Avandia’s risks and when it did learn of new information concerning Avandia’s risks, did not provide the FDA with that information in a timely manner.

Even the FDA criticized Galaxo’s own funded study that said Avandia isn’t linked to a higher risk of heart attacks or strokes.

At one time, Avandia had 2006 global sales of $2.5 billion. After its Black Box Warning, sales slipped to $1.2 billion in 2009. A rival drug, Actos, had sales of over $4 billion last year. Actos and Avandia lower glucose levels for 23 million Americans with Type 2 diabetes.

Interestingly, Actos has never been linked to serious cardiovascular risks.

Back To Main Avandia Page »